Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Drug Interactions in Inflammatory Bowel Disease

Irving, Peter M., M.D., M.R.C.P.1; Shanahan, Fergus, M.D., F.R.C.P., F.R.C.P.I.2; Rampton, David S., D.Phil., F.R.C.P.3

American Journal of Gastroenterology: January 2008 - Volume 103 - Issue 1 - p 207–219
CLINICAL REVIEW: BENCH TO BEDSIDE REVIEW
Buy
CME

Patients with inflammatory bowel disease (IBD) often require a combination of drugs, some of which are taken for many years, to control their disease. Some of these drugs have potentially serious side effects, which may be initiated or exacerbated by interaction with other agents used to treat IBD. Furthermore, patients with IBD may take treatment for other, unrelated conditions. It is important for doctors who manage patients with IBD to be aware of, and thereby minimize, the dangers presented by such drug interactions. In this review, we summarize the common and important interactions of drugs used in patients with IBD, including some that may be of therapeutic benefit. Particular attention is paid to interactions that occur where both drugs are used to treat IBD.

1Department of Gastroenterology and Medicine, Box Hill Hospital and Monash University, Melbourne, Australia; 2Alimentary Pharmabiotic Centre, University College Cork, National University of Ireland, Cork, Ireland; and 3Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts and The London, Queen Mary School of Medicine, London, United Kingdom

Reprint requests and correspondence: Professor David Rampton, Endoscopy Unit, Royal London Hospital, London E1 1BB, UK.

Received April 16, 2007; accepted July 23, 2007.

CONFLICT OF INTERESTGuarantor of the article: David Rampton, D.Phil., F.R.C.P.

Specific author contributions: All authors collaborated in study and design. Relevant interactions were initially identified by Peter Irving and were added to or modified by the other authors. The first and subsequent drafts of the manuscript were written by Peter Irving with critical comment, revision, and input from the other authors.

Financial support: None.

Potential competing interests: Peter M. Irving has received financial support to attend Digestive Diseases Week (2007) from AstraZeneca and Schering Plough. David S. Rampton attends Medical Advisory Board meetings of Ferring Pharmaceuticals UK twice yearly. He was financially supported in 2006 by Procter & Gamble for attendance at the British Society of Gastroenterology meeting (Birmingham) and United European Gastroenterology Week (Berlin). He has also been paid small fees for invited lectures at commercially supported meetings in the U.K. by Ferring, Schering Plough, and Procter & Gamble in the last 2 yr and co-organizes biannual meetings of the London IBD Forum supported financially by Ferring UK and Schering Plough. He also attends weekly gastroenterology and IBD clinical meetings at which a sandwich lunch is provided free by a range of drug companies. Fergus Shanahan is affiliated with a university campus-based company (Alimentary Health Ltd) and has received grants from and/or served as a consultant to GlaxoSmithKline and the Procter & Gamble Co. The content of this article was neither influenced nor constrained by these facts.

© The American College of Gastroenterology 2008. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website